NCT06758583View on ClinicalTrials.gov

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

April 12, 2025

Study Completion Date

April 25, 2025

Conditions
Overweight and Obesity
Interventions
DRUG

Dapiglutide 7.5 mg

Single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
collaborator

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

lead

Zealand Pharma

INDUSTRY